{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:08:47Z","timestamp":1776874127538,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology of Taiwan","doi-asserted-by":"crossref","award":["107-2320-B-006-070-MY3"],"award-info":[{"award-number":["107-2320-B-006-070-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40259-022-00516-y","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T10:02:56Z","timestamp":1646128976000},"page":"205-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study"],"prefix":"10.1007","volume":"36","author":[{"given":"Wan-Ju Annabelle","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Chieh","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Chi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swu-Jane","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-7652","authenticated-orcid":false,"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"516_CR1","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1056\/NEJMcibr1204973","volume":"367","author":"JT Rosenbaum","year":"2012","unstructured":"Rosenbaum JT. Eyeing macular degeneration\u2014few inflammatory remarks. N Engl J Med. 2012;367:768\u201370.","journal-title":"N Engl J Med"},{"key":"516_CR2","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606\u201317.","journal-title":"N Engl J Med"},{"key":"516_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10792-016-0241-4","volume":"37","author":"Y Xu","year":"2017","unstructured":"Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37:325\u201332.","journal-title":"Int Ophthalmol"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787\u201394.","journal-title":"Eye (Lond)"},{"key":"516_CR5","first-page":"785","volume":"13","author":"F Semeraro","year":"2014","unstructured":"Semeraro F, Morescalchi F, Duse S, Gambicorti E, Romano MR, Costagliola C. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Expert Opin Drug Saf. 2014;13:785\u2013802.","journal-title":"Expert Opin Drug Saf"},{"key":"516_CR6","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/jcm9051522","volume":"9","author":"AA Plyukhova","year":"2020","unstructured":"Plyukhova AA, Budzinskaya MV, Starostin KM, et al. Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies. J Clin Med. 2020;9:1522.","journal-title":"J Clin Med"},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00417-018-4141-3","volume":"256","author":"M Morioka","year":"2018","unstructured":"Morioka M, Takamura Y, Yamada Y, Matsumura T, Gozawa M, Inatani M. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2018;256:2301\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"516_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000444497","volume":"56","author":"S Demirel","year":"2016","unstructured":"Demirel S, Bilici S, Bat\u0131o\u011flu F, \u00d6zmert E. Is there any difference between ranibizumab and aflibercept injections in terms of inflammation measured with anterior chamber flare levels in age-related macular degeneration patients: a comparative study. Ophthalm Res. 2016;56:35\u201340.","journal-title":"Ophthalm Res"},{"key":"516_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s10384-019-00698-z","volume":"64","author":"T Shiraya","year":"2020","unstructured":"Shiraya T, Kure K, Araki F, Kato S, Kaiya T. Correlation between anterior chamber flare changes and diabetic macular edema after intravitreal injection of ranibizumab and aflibercept. Jpn J Ophthalmol. 2020;64:250\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"516_CR10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1097\/IAE.0b013e3181e095c0","volume":"30","author":"M Funk","year":"2010","unstructured":"Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010;30:1412\u20139.","journal-title":"Retina"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ophtha.2005.10.030","volume":"113","author":"H Funatsu","year":"2006","unstructured":"Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2006;113:294\u2013301.","journal-title":"Ophthalmology"},{"key":"516_CR12","doi-asserted-by":"crossref","unstructured":"Scondotto G, Crisafulli S, Antonazzo IC, Virgili G, Trifir\u00f2 G, Sultana J. Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research [published online ahead of print, 2021 Jul 27].\u00a0Expert Opin Drug Saf. 2021;1\u201310.","DOI":"10.1080\/14740338.2021.1957829"},{"key":"516_CR13","doi-asserted-by":"publisher","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","volume":"40","author":"LY Lin","year":"2018","unstructured":"Lin LY, Warren-Gash C, Smeeth L, Chen PC. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health. 2018;40:e2018062.","journal-title":"Epidemiol Health."},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, et al. Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349\u201358.","journal-title":"Clin Epidemiol"},{"key":"516_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075","volume":"201","author":"CL Cheng","year":"2015","unstructured":"Cheng CL, Chien HC, Lee CH, Lin SJ, Yang YH. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol. 2015;201:96\u2013101.","journal-title":"Int J Cardiol"},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.JE20140076","volume":"24","author":"CL Cheng","year":"2014","unstructured":"Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol. 2014;24:500\u20137.","journal-title":"J Epidemiol"},{"key":"516_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pds.2087","volume":"20","author":"CL Cheng","year":"2011","unstructured":"Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236\u201342.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"516_CR18","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1097\/IAE.0000000000001084","volume":"36","author":"TH Rim","year":"2016","unstructured":"Rim TH, Lee CS, Lee SC, Kim DW, Kim SS. Intravitreal ranibizumab therapy for neovascular age-related macular degeneration and the risk of stroke: a national sample cohort study. Retina. 2016;36:2166\u201374.","journal-title":"Retina"},{"key":"516_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ajo.2016.03.026","volume":"166","author":"M Etminan","year":"2016","unstructured":"Etminan M, Maberley DA, Babiuk DW, Carleton BC. Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration. Am J Ophthalmol. 2016;166:205.","journal-title":"Am J Ophthalmol"},{"key":"516_CR20","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ophtha.2014.03.022","volume":"121","author":"SJ Park","year":"2014","unstructured":"Park SJ, Lee JH, Woo SJ, et al. Age-related macular degeneration: prevalence and risk factors from Korean National Health and Nutrition Examination Survey, 2008 through 2011. Ophthalmology. 2014;121:1756\u201365.","journal-title":"Ophthalmology"},{"key":"516_CR21","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"516_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/14740338.2019.1643838","volume":"18","author":"C Costagliola","year":"2019","unstructured":"Costagliola C, Morescalchi F, Duse S, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update. Expert Opin Drug Saf. 2019;18:803\u201315.","journal-title":"Expert Opin Drug Saf"},{"key":"516_CR23","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1167\/iovs.15-16686","volume":"56","author":"C Zehetner","year":"2015","unstructured":"Zehetner C, Bechrakis NE, Stattin M, et al. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy. Invest Ophthalmol Vis Sci. 2015;56:3279\u201386.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"516_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000119877","volume":"40","author":"N Miyamoto","year":"2008","unstructured":"Miyamoto N, de Kozak Y, Normand N, et al. PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema. Ophthalm Res. 2008;40:203\u20137.","journal-title":"Ophthalm Res"},{"key":"516_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","volume":"98","author":"S Julien","year":"2014","unstructured":"Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98:813\u201325.","journal-title":"Br J Ophthalmol"},{"key":"516_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3341\/kjo.2019.0120","volume":"34","author":"SY Ryu","year":"2020","unstructured":"Ryu SY, Kim J, Kim DW, Chung EJ. Association between ranibizumab injections and risk of acute myocardial infarction in age-related macular degeneration: a case-crossover study. Korean J Ophthalmol. 2020;34:150\u20137.","journal-title":"Korean J Ophthalmol"},{"key":"516_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41433-020-0911-3","volume":"35","author":"J Kim","year":"2021","unstructured":"Kim J, Kim DW, Kim DH, Ryu SY, Chung EJ. Risk of stroke associated with intravitreal ranibizumab injections in age-related macular degeneration: a nationwide case-crossover study. Eye (Lond). 2021;35:601\u20137.","journal-title":"Eye (Lond)"},{"key":"516_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/bjophthalmol-2020-316373","volume":"105","author":"HL Jeon","year":"2021","unstructured":"Jeon HL, Byun SJ, Pratt NL, Sultana J, Park SJ, Shin JY. Cardiovascular risk in patients receiving ranibizumab for exudative age-related macular degeneration: a nationwide self-controlled case-series study. Br J Ophthalmol. 2021;105:543\u20138.","journal-title":"Br J Ophthalmol"},{"key":"516_CR29","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.3928\/23258160-20190503-14","volume":"50","author":"MR Starr","year":"2019","unstructured":"Starr MR, Dalvin LA, AbouChehade JE, et al. Classification of strokes in patients receiving intravitreal anti-vascular endothelial growth factor. Ophthalm Surg Lasers Imaging Retina. 2019;50:e140\u201357.","journal-title":"Ophthalm Surg Lasers Imaging Retina"},{"key":"516_CR30","doi-asserted-by":"publisher","first-page":"e022031","DOI":"10.1136\/bmjopen-2018-022031","volume":"9","author":"B Pham","year":"2019","unstructured":"Pham B, Thomas SM, Lillie E, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open. 2019;9:e022031.","journal-title":"BMJ Open"},{"key":"516_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","volume":"137","author":"LA Dalvin","year":"2019","unstructured":"Dalvin LA, Starr MR, AbouChehade JE, et al. Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol. 2019;137:483\u201390.","journal-title":"JAMA Ophthalmol."},{"key":"516_CR32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.oret.2018.04.018","volume":"2","author":"MA Zarbin","year":"2018","unstructured":"Zarbin MA, Francom S, Grzeschik S, et al. Systemic safety in ranibizumab-treated patients with neovascular age-related macular degeneration: a patient-level pooled analysis. Ophthalmol Retina. 2018;2:1087\u201396.","journal-title":"Ophthalmol Retina."},{"key":"516_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.oret.2018.01.010","volume":"2","author":"PU Dugel","year":"2018","unstructured":"Dugel PU, Singh N, Francom S, Cantrell RA, Grzeschik SM, Fung AE. The systemic safety of ranibizumab in patients 85 years and older with neovascular age-related macular degeneration. Ophthalmol Retina. 2018;2:667\u201375.","journal-title":"Ophthalmol Retina."},{"key":"516_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40259-021-00497-4","volume":"35","author":"WA Lee","year":"2021","unstructured":"Lee WA, Shao SC, Liao TC, Lin SJ, Lai CC, Lai EC. Comparative risk of arterial thromboembolic events between aflibercept and ranibizumab in patients with maculopathy: a population-based retrospective cohort study. BioDrugs. 2021;35:579\u201388.","journal-title":"BioDrugs"},{"key":"516_CR35","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","volume":"96","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96:572\u201380.","journal-title":"Kidney Int"},{"key":"516_CR36","doi-asserted-by":"publisher","first-page":"579603","DOI":"10.3389\/fmed.2020.579603","volume":"7","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Tran NT, Patel SS, et al. Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors vegf blockade-related tma after intravitreal use. Front Med (Lausanne). 2020;7:579603.","journal-title":"Front Med (Lausanne)."},{"key":"516_CR37","doi-asserted-by":"publisher","first-page":"e113701","DOI":"10.1371\/journal.pone.0113701","volume":"9","author":"A Tschulakow","year":"2014","unstructured":"Tschulakow A, Christner S, Julien S, Ludinsky M, van der Giet M, Schraermeyer U. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE. 2014;9:e113701.","journal-title":"PLoS ONE"},{"key":"516_CR38","doi-asserted-by":"publisher","first-page":"e0150688","DOI":"10.1371\/journal.pone.0150688","volume":"11","author":"C Arnott","year":"2016","unstructured":"Arnott C, Punnia-Moorthy G, Tan J, Sadeghipour S, Bursill C, Patel S. The vascular endothelial growth factor inhibitors ranibizumab and aflibercept markedly increase expression of atherosclerosis-associated inflammatory mediators on vascular endothelial cells. PLoS ONE. 2016;11:e0150688.","journal-title":"PLoS ONE"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00516-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00516-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00516-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T11:31:59Z","timestamp":1649244719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00516-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00516-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"10 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The Ministry of Science and Technology of Taiwan (107-2320-B-006-070-MY3). The funding source had no role in the design, analysis, interpretation, or reporting of results, or in the decision to submit the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Data sharing is not applicable because data analysis and management were permitted only within Taiwan\u2019s Health and Welfare Data Science Center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The SAS codes applied for this study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This study was approved by the Institutional Review Board of National Cheng Kung University Hospital (A-ER-106-501).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate\/Publish"}},{"value":"WJAL and ECCL substantially contributed to the study conception and design. TCL substantially contributed to the data acquisition and analysis. All authors substantially contributed to the data interpretation and manuscript writing, and gave final approval for the manuscript submission. ECCL is the guarantor for the whole of this study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}